Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-08-21
1997-04-22
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
53612312, 5361231, 536124, 536127, A61K 31715, C07H 100, C07H 300, C08B 3700
Patent
active
056229399
ABSTRACT:
The present invention relates to neutral soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1, TNF and leukotrienes) that can cause detrimental side effects, such as fever and inflammation.
REFERENCES:
patent: 4138479 (1979-02-01), Truscheit et al.
patent: 4237266 (1980-12-01), Sugiura et al.
patent: 4707471 (1987-11-01), Larm et al.
patent: 4739046 (1988-04-01), DiLuzio et al.
patent: 4761402 (1988-08-01), Williams et al.
patent: 4810646 (1989-03-01), Jamas et al.
patent: 5057503 (1991-10-01), Czop et al.
Bacon, J. et al., "Glucan Components of the Cell Wall of Baker's Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ulstrastructure", Chemical Abstracts 71 (No. 23):109171(109168c), (Dec. 8, 1969).
Fleet, G.H., et al., "Isolation and Composition of an Alkali-soluble Glucan from the Cell Walls of Saccharomyces cerevisiae", Journal of General Microbiology, 94:180-192 (1976).
Miyazaki, T., et al., "Structural Examination of Antitumour, Water-Soluble Glucans from Grifora umbellata by Use of Four Types of Glucanese," Carbohydrate Researach, 65:235-243 (1978).
Reiskind, J.B. and Mullins, J.T., "Molecular Architecture of the Hyphal Wall of Achlya ambisexualis Raper. II. Ultrastructural Analyses and a Proposed Model," J. Microbiol., 27:1100-1105 (1981).
Latge, J.P., et al., "Composition chimique et ultrastructure des parois des corps hyphaux et des azygospores de Conidiobolus obscurus, " J. Microbiol., 30:1507-1521 (1984).
Sherwood, E.R., et al., "Soluble Glucan and Lymphokine-activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," Chemical Abstracts, 108:179752V (1988).
Hara, C., et al., "A Branched (1-3)-.beta.-D-Glucan From a Water Extract of Dictyophora indusiata Fisch," Carb. Res., 145:237-246 (1986).
Goldman, R., "Induction of a .beta.-1, 3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-dihydroxyvitamin D.sub.3," Immunology, 63:319-324 (1988).
Konopski, A., et al., "Phagocytosis of -1, 3-D-Glucan-Derivatized Microbeads by Mouse peritoneal Macrophages Involves Three Different Receptors," Scand. J. Immunol., 33:297-306 (1991).
Bacon, J.S.D., et al., "Glucan Components of the Cell Wall of Bakers' Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure," Chemical Abstracts, 71:109168c (1969).
Williams, D.L., et al., "Development of a Water-Soluble, Sulfated (1-3)- -D-Glucan Biological Response Modifier Derived from Saccharomyces cerevisiae," Carbohydrate Research, 235:247-257 (1992).
Williams, D. L., et al., "A sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," Develop. Biol. Standard., 77:129-136 (1992).
Williams, D.L., et al., "Development, Physicochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived from Saccharomyces cerevisiae," Immunopharmacology, 22:139-156 (1991).
Pretus, H.A., et al., "Isolation, Physicochemical Characterization and Preclinical Efficacy Evaluation of Soluble Scleroglucan.sup.1," The Journal of Pharmacology and Experimental Therapeutics, 500-510 (1991).
Janusz, M.J. et al., "Isolation of soluble yeast .beta.-Glucan That Inhibit Human Monocyte Phagocytosis Mediated by .beta.-Glucan Receptors", J. Immunol. 137:3270-3276 (Nov. 15, 1986).
Manners, D.J. et al., "The Structure of a .beta.-(1.fwdarw.3)-D-Glucan from Yeast Cell Walls", Biochem. J. 135:19-30 (1973).
Williams, D.L. et al., "Pre-clinical Safety Evaluation of Soluble Glucan", Chemical Abstracts 109:66566q (1988).
Fleet, G.H. et al., "Isolation and Composition of an Alkali-soluble Glucan from the Cell Walls of Saccharomyces Cerevisiae", Chemical Abstracts 85:89819z (1976).
Bacon, J. et al., "The Glucan Components of the Cell Wall of Baker's Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure", Biochem. J. 114:557-567 (1969).
Onderdonk, A.B. et al., "Anti-Infective Effect of Poly-.beta.1-6-Glucotrisyl-.beta.1-3-Glucopyranose Glucan In Vivo", Infect. Immun. 60:1642-1647 (1992).
Abel, G. and J.K. Czop, "Activation of Human Monocyte GM-CSF and TNF-.varies. Production by Particulate Yeast Glucan", International Congress For Infectious Diseases, Montreal, Canada (Abstract), Jul. 15-19, 1990.
Chihara, G. et al., "Lentinan as a Host Defense Potentiator (HPD)", Int. J. Immunotherapy V(4):145-154 (1989).
Sherwood, E.R. et al., "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan", Int. J. Ummunophamac. vol. 9,No. 3: 261-267 (1987).
Williams, D.L. et al., "Pre-Clinical Safety Evaluation of Soluble Glucan", Int. J. Immunopharmac. vol. 10,No. 4:405-414 (1988).
Browder, W. et al., "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient", Ann. Surg. pp. 605-613 (1990).
Jamas et al., "A Novel Class of Macrophage-Activating Immunomodulators", ACS Symposium Series, Polymeric Drugs and Delivery Systems, Chapter 5, pp. 44-51 (1991).
Easson, Jr. D. Davidson
Jamas Spiros
Ostroff Gary R.
Alpha-Beta Technology, Inc.
Kight John
White Everett
LandOfFree
Glucan preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucan preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucan preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-341617